You are here
HemoShear Therapeutics, LLC
UEI: EYEHGTVJK567
# of Employees: 25
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism
Amount: $1,171,782.00Fast Track SBIRIdentification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism defectsABSTRACT There are very few reliable methods to study and unders ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Validation of targets for therapeutic intervention in NASH
Amount: $1,862,227.00Direct to Phase II SBIRValidation of targets for therapeutic intervention in NASHABSTRACT Non alcoholic steatohepatitisNASHis part of the progressive disease spectrum of non alcoholic fatty liver dise ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Validation of a human in vitro system of hepatic steatohepatitis
Amount: $1,210,475.00Phase II SBIR Validation of a human in vitro system of hepatic steatohepatitis ABSTRACT Non alcoholic steatohepatitis NASH is part of the progressive disease spectrum of non alcoholic fatty liver ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism
Amount: $1,215,005.00Fast Track SBIR Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism defects ABSTRACT There are very few reliable methods to study and unde ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
IGF OT IGF SBIR PHASE II TOPIC TITLE VALIDATION OF THE HEMOSHEAR TUMOR MICROENVIRONMENT SYSTEM FOR DRUG DISCOVERY AND DEVELOPMENT
Amount: $1,985,884.00Not Available
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Development of a DIVI platform for issue resolution in pre-clinical drug development.
Amount: $1,199,998.00DESCRIPTION provided by applicant Drug induced vascular injury DIVI is a common phenomenon in pre clinical animal studies and is typically characterized by hemorrhage vascular endothelial and sm ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Development of an iPSC-derived human hepatocyte platform for drug development.
Amount: $1,689,857.00DESCRIPTION provided by applicant Human inducible pluripotent stem cells iPSCs proliferate readily and can be terminally differentiated into hepatocytes which potentially makes them an attractiv ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Development of an in vitro system of human hepatic steatosis.
Amount: $255,128.00DESCRIPTION provided by applicant Non alcoholic fatty liver disease NAFLD is a rapidly emerging public health crisis affecting up to of Type diabetics and of obese individuals Glucose ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.
Amount: $463,475.00DESCRIPTION provided by applicant Liver cell based systems are widely used to study drug metabolism toxicity and liver disease However the poor correlation between in vitro data and clinical out ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
Development of an iPSC-derived human vascular system for drug discovery and devel
Amount: $249,013.00DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health